Report_ID;Date;Clinical_Note_Raw;Drug_Suspected;Adverse_Event_Extracted;Severity_Grade;Action_Required
RPT-2025-001;01/12/2025;Male patient, 65yo, active treatment with Opdivo (nivolumab) cycle 4. Presents to ER with progressive dyspnea and non-productive dry cough for 72h. Baseline O2 Sat 92%. Chest CT shows bilateral ground-glass opacities. High suspicion of G2 immune-mediated pneumonitis. Prednisone 1mg/kg initiated.;;;;
RPT-2025-002;02/12/2025;Female, 42yo. Yervoy cycle review. Reports intense pruritus on arms and upper trunk, with mild maculopapular rash (<10% BSA). No fever. No mucosal involvement. Appears to be Grade 1 skin toxicity. Antihistamines and topical corticosteroids prescribed.;;;;
RPT-2025-003;03/12/2025;Emergency: Patient 55yo on Opdivo+Yervoy combo. Severe diarrhea (>7 stools/day over baseline), colicky abdominal pain, and mild rectal bleeding. Moderate dehydration. Possible Grade 3 immune colitis. Immediate admission for fluid therapy and IV methylprednisolone. Immunotherapy suspended.;;;;
RPT-2025-004;04/12/2025;Sprycel (dasatinib) follow-up. Patient reports occasional headache and mild fatigue at end of day. Normal labs, no pleural effusion on X-ray. Acceptable tolerance. Continue same dose.;;;;
RPT-2025-005;05/12/2025;Patient 70yo, MM on Revlimid tx. Presents with fever of 38.5C and severe neutropenia (ANC < 500). Diagnosis: Febrile Neutropenia (Grade 4). Broad-spectrum antibiotics and G-CSF initiated. Isolation admission.;;;;
